Managed Care Considerations for a First-in-Class M1/M4 Muscarinic Agonist for the Treatment of Adults With Schizophrenia

home / publications / supplement / managed-care-considerations-for-a-first-in-class-m1-m4-muscarinic-agonist-for-the-treatment-of-a
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo